Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Total Debt (2016 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Total Debt for 4 consecutive years, with $11.0 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Total Debt fell 54.81% year-over-year to $11.0 million, compared with a TTM value of $11.0 million through Mar 2023, down 54.81%, and an annual FY2022 reading of $16.8 million, down 30.49% over the prior year.
  • Total Debt was $11.0 million for Q1 2023 at Alaunos Therapeutics, down from $16.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $24.5 million in Q2 2022 and bottomed at $11.0 million in Q1 2023.
  • Average Total Debt over 3 years is $21.1 million, with a median of $24.1 million recorded in 2021.
  • The sharpest move saw Total Debt decreased 6.37% in 2022, then tumbled 54.81% in 2023.
  • Year by year, Total Debt stood at $24.1 million in 2021, then tumbled by 30.49% to $16.8 million in 2022, then plummeted by 34.46% to $11.0 million in 2023.
  • Business Quant data shows Total Debt for TCRT at $11.0 million in Q1 2023, $16.8 million in Q4 2022, and $22.7 million in Q3 2022.